Proton and heavy-ion therapy in China has changed shape over the past twelve months, and not in the way most overseas patients were told to expect. The machines are no longer concentrated in the two or three cities a foreign searcher can name from memory, and in November a provincial cancer centre in eastern China was licensed to run a delivery mode — proton FLASH — that compresses the beam-on time of a single session to the scale of seconds. Neither change is about clinical superiority. Both are about your calendar, and for someone applying for a visa, arranging care abroad, and burning limited paid leave, the calendar is the real constraint.
Here is what was announced, what the public cost references actually cover, and the three separate permissions you need to confirm before you buy a ticket.
What Changed in November 2026, and Why Geography Matters
Shandong First Medical University Affiliated Cancer Hospital, also known as Shandong Provincial Cancer Hospital, announced on 11 November 2026 that the radiation safety permits for its heavy-ion therapy装置 and its proton FLASH project were approved together by the Ministry of Ecology and Environment (hospital announcement). Per the same announcement, the hospital describes itself as the first institution in China to receive radiation safety clearance for a domestically built multi-particle heavy-ion system — carbon, helium and oxygen ions in addition to protons — the first to be licensed for proton FLASH beam delivery, and the first domestic heavy-ion installation equipped with a 360-degree rotating treatment room.
The rotating gantry detail is easy to under-read. A fixed horizontal beam line forces the patient to be repositioned for every angle; a rotating room changes how treatments are scheduled and which anatomical sites are practical. For a patient travelling from abroad, the more useful reading is simpler: capacity and site choice are moving away from the Shanghai-and-Guangzhou framing that dominates almost every English-language page on this subject.
The second number worth knowing is the size of the pipeline. Reporting in the Chinese medical trade press on 10 December 2025 noted that the National Health Commission's December 2025 announcement of Class A large medical equipment configuration permits added five proton or heavy-ion institutions, bringing the cumulative total to 42 hospitals authorised to configure such systems. That is a licensing statistic, not a treatment-capacity statistic — a point that matters more than any price figure below.
If you are weighing particle therapy against other oncology options in China, the wider comparison is in our cancer treatment in China service overview, and the modality-specific basics are covered in the proton therapy in China guide.
What Proton FLASH Actually Shortens — and What It Does Not
FLASH is ultra-high-dose-rate radiotherapy: the dose for a fraction is delivered in a very brief burst rather than over a conventional delivery window. The practical consequences break into three groups, and conflating them is the most common mistake in patient-facing summaries of this technology.
What genuinely improves. Less time lying still on the couch per session is meaningful for patients with pain, spinal instability, or difficulty holding a position. Higher throughput per treatment room is meaningful for you indirectly: it is one of the few levers that expands how many patients a licensed suite can see in a day, which is the bottleneck that determines whether your first fraction happens in March or in July.
What does not change. Simulation imaging, plan design, dose verification, quality assurance sign-off, and hospital approval of the treatment intent all take the same time as before. A FLASH permit does not compress the queue for the machine, and it does not compress the two-to-three-week lead from records review to a booked slot that many international departments quote.
What is not established. Whether FLASH alters tumour control or normal-tissue tolerance relative to conventional proton delivery is a clinical question that its answer is a treating radiation oncologist's, not a press release's. Our own position: a treatment plan — particle type, energy, fraction number, and whether particle therapy is appropriate for your site at all — must be assessed in person by a licensed physician after review of your records. Anyone who commits to a fraction count from an email is guessing.
Three Permissions, Three Different Questions: A Comparison Table
The single most valuable thing to internalise before you contact a hospital is that the English phrase "approved for proton therapy in China" collapses at least three separate administrative facts. This is the table we ask patients to fill in during the first call.
| Permission layer | Issuing body | What it proves | What it does not prove |
|---|---|---|---|
| Class A large medical equipment configuration permit | National Health Commission | The hospital is authorised to install and operate a proton or heavy-ion system of that class | That a beam line is built, commissioned, or clinically in use |
| Radiation safety permit | Ministry of Ecology and Environment | Radiation activities at that facility, for that device, are cleared — as with the paired heavy-ion and proton FLASH approvals announced in November 2026 | Which indications are accepted, or whether foreign self-pay patients may be booked |
| International / special-need intake policy | The hospital itself, via its international medical department | Whether the institution will register, schedule, invoice and issue records to a non-Chinese self-pay patient | Your insurer's willingness to pay, or the final price |
Ask each question separately and record each answer separately. A department that answers "yes, we have the permit" to a question you asked about three different things is not answering your question.
What Proton and Heavy-Ion Therapy in China Costs in Public Terms
In an article published on its site on 8 May 2026, South China's national healthcare-payment authority — the National Healthcare Security Administration — stated that localities have set government guidance prices for these treatments, with a full proton course around RMB 170,000 and heavy-ion treatment within RMB 200,000. That is the first time an official Chinese source has given most overseas readers a defensible order of magnitude rather than a broker's estimate.
Read what it is and is not:
| Cost line | Public anchor | What you still need in writing |
|---|---|---|
| Proton, full course | Government guidance price, ~RMB 170,000 (NHSA, 8 May 2026) | The hospital's self-pay quotation for your specific plan and fraction number |
| Heavy-ion, full course | Government guidance price, within RMB 200,000 (same source) | Whether a multi-particle line is billed differently from a carbon-only line |
| Consultation, imaging, pathology review, inpatient days | Not included in the figures above | Itemised quotation per line, in the currency you will pay in |
| Special-need / international-department services | Market-adjusted pricing, capped at 10% of billable items and fees, and excluded from basic pooling-fund payment | Whether the service is self-pay only, and whether direct billing exists |
| Interpreter, escort, accommodation, ground transport | Set outside the hospital | Whether your insurer covers any of it, and your own leave budget |
Guidance prices are domestic public-pricing references, not international patient invoices. The honest framing for your planning is: the beam itself is the predictable part; the surrounding line items are where quotations diverge, and the hospital's actual quotation is the only number to plan against. Our proton therapy service page explains how we get an itemised quote rather than a range.
Why the Calendar Is the Scarce Resource, Not the Machine
A regulatory detail in the same round of 2026 local rule-making explains the scheduling pressure that foreign patients feel as "no availability before June". Under the 2021 pilot plan on medical service price reform issued by the National Healthcare Security Administration and seven other departments, special-need medical services may be priced at market rates, but the number of chargeable items and the share of fees they represent may not exceed 10% of a public hospital's activity. In 2026 the local implementation rules arrived in bulk: Shandong's took effect from 20 June 2026, with special-need fees borne entirely by the patient and excluded from basic pooling-fund payment, and Hubei split the same principle into three separate 10% ceilings — item count, fee share, and share of special-need beds (sector summary).
The consequence is structural. A public hospital cannot solve a queue for international patients by simply opening more beds or adding more chargeable services, and money does not buy your way past the ceiling. The National Health Commission's August 2026 outline of the 15th Five-Year Plan for universal healthcare coverage says policy for special-need and international service pricing will be explored further, and new international units keep opening — Beijing Children's Hospital's international department began operating in January 2026 — but expansion is gradual and unevenly distributed by specialty.
Two practical implications follow:
- Ask for the earliest treatable date, not the earliest appointment date. Booking a consultation three weeks out is worthless if the first fraction cannot be scheduled for four months.
- Ask which city you would actually be treated in. Multi-city plans are common in particle therapy — simulation in one place, weekly treatment elsewhere — and each transfer costs you leave days and adds records and imaging work.
Visa stay length sits underneath all of this. Treatment planning and permitted stay have to be reconciled before, not after, arrival; our China medical visa guide covers the categories and supporting documents, and booking support is where we convert a date range into a confirmed slot.
The Four Questions to Put to the International Medical Department
Write these down and send them in the first email rather than the third.
- Which permit covers the exact room and beam line I would be treated on, and can you provide the document reference? Distinguish the configuration permit from the radiation safety permit, and note that the November 2026 Shandong announcement covered both a heavy-ion装置 and a proton FLASH project as separate clearances.
- Are you currently accepting foreign self-pay patients on that system, and what is the earliest treatable date? Get the answer as a date, not as "usually a few weeks".
- What is the itemised, all-in self-pay quotation for my indication, including simulation, planning, per-fraction delivery, hospital days, and the international-department service charge? Confirm whether it is billed entirely outside basic medical insurance.
- If systemic therapy is part of your plan: does the hospital have its own international pharmacy and access to drugs outside the domestic formulary? This is where Chinese centres now differ sharply. Peking Union Medical College Hospital's international medical department pharmacy stocks more than 400 imported medicines and the hospital is inside Beijing's pilot whitelist for clinically urgently needed drugs, which allows out-of-catalogue agents to be requested by the treating specialty under policy; a 2025 measure also created a commercial-insurance innovative-drug catalogue with exclusions from certain basic-insurance cost controls, and designated hospitals were expected to hold formulary committee meetings by the end of February 2026 (summary). Absent those two facts at a given hospital, a drug you read about is not a drug you can be prescribed there.
If Your Question Is a Drug, Not a Beam
Cancer patients comparing systems usually ask about the drug first and the radiation second, so it is worth separating the tracks. The FDA's 2026 novel drug approval list ran to 54 entries as of mid-November, with several relevant to the indications international patients most often ask us to compare: on 17 November 2026, Nelkarmi (neladalkib) for previously treated advanced or metastatic ALK-positive non-small-cell lung cancer, and on 16 November 2026, Wilserdly (giredestrant) for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer (FDA list). None of those dates tells you anything about Chinese availability, which moves independently and in the opposite direction as often as not. The discipline is the same one applied to the permits above: distinguish "just approved" from "already bookable" and "already on a formulary", and never arrange cross-border travel on a headline.
A Planning Sequence That Survives Contact With Reality
| Stage | What must be true before you book anything |
|---|---|
| Records assembly | Histology report, staging imaging in DICOM, prior treatment dates and doses, current bloodwork, all translated |
| Remote physician review | A clinician states whether particle therapy is indicated for your site at all, before you compare cities |
| Permission and quote check | Configuration permit, radiation safety permit and self-pay intake confirmed separately; itemised quotation in hand |
| Travel and visa alignment | Earliest treatable date confirmed, stay length and leave window reconciled |
| Simulation and planning | Imaging, plan design and quality assurance completed on site |
| Treatment | Daily delivery; FLASH shortens the beam-on window, not the workup around it |
| After return | Discharge summary, dosimetry records and follow-up schedule in a form your home physician can read |
The first three rows are where foreign patients lose the most time, and none of them require a plane ticket. A related question — which centre for which tumour — is treated in our complete guide to medical tourism in China and in our hospital directory.
Who Should Reconsider the Trip
Particle therapy is not a general upgrade. For many tumour sites conventional photon techniques remain standard, and for widely metastatic disease the systemic-therapy question usually dominates the local-therapy question. If your reason for considering China is price alone, note that the guidance figures above are domestic references and that a multi-city plan with an international-department surcharge can look very different from RMB 170,000. If your reason is a specific machine, a specific indication, or a drug pathway that your home system does not offer, the case is different — and that is exactly the case that requires the four questions answered in writing first.
How OriEast Supports This
OriEast is not a clinic and does not assess your treatment. What we do is operational: certified medical translation of your records and imaging reports, verification of the three permission layers with a named department contact, itemised quotations rather than ranges, appointments and treatable-date confirmation, on-the-ground interpretation, and coordination between the Chinese team and your physician at home.
Submit your records for case evaluation and we will tell you, before you commit to travel, whether any Chinese centre can plausibly treat your indication and on what date. For pricing, scheduling or insurance questions, use the inquiry form or contact us directly.